TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
American Society of Clinical Oncology (ASCO)
Online
2022-06-04
DOI
10.1200/jco.21.02506
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study
- (2021) Kimberly K. Leslie et al. GYNECOLOGIC ONCOLOGY
- Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
- (2020) Alicia León-Castillo et al. JOURNAL OF CLINICAL ONCOLOGY
- Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
- (2020) Eun Young Kang et al. MODERN PATHOLOGY
- PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
- (2020) Anne Sophie V M van den Heerik et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
- (2020) David S. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens
- (2019) Anna Plotkin et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies
- (2019) Naveena Singh et al. JOURNAL OF PATHOLOGY
- A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer
- (2018) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial
- (2018) B.G. Wortman et al. GYNECOLOGIC ONCOLOGY
- Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
- (2016) Ellen Stelloo et al. CLINICAL CANCER RESEARCH
- A clinically applicable molecular-based classification for endometrial cancers
- (2015) A Talhouk et al. BRITISH JOURNAL OF CANCER
- USA Endometrial Cancer Projections to 2030: should we be concerned?
- (2014) M Aamir Sheikh et al. Future Oncology
- TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
- (2014) PAVLA BRACHOVA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
- (2013) Pavla Brachova et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis
- (2011) Anna Yemelyanova et al. MODERN PATHOLOGY
- p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes
- (2009) Karuna Garg et al. MODERN PATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started